by Jason Heaviland | Mar 2, 2026
Chemical Exposure Profiling of Alzheimer’s Patients This webinar presents a comprehensive overview of chemical exposure profiling in Alzheimer’s patients using Panome Bio’s Targeted Exposomics™ and Discovery Exposomics™ platforms. Learn how quantitative exposure...
by Jason Heaviland | Feb 27, 2026 | Uncategorized
For 20 years, genomics has promised precision medicine. And it delivered. For rare diseases and select cancers. But for most chronic conditions?
Genetics explains only a fraction of risk. Type 2 diabetes. Alzheimer’s disease. Autoimmune disorders. Metabolic syndrome....
by Janine Rodriguez | Nov 25, 2025
ChatGJP: Insights from Gary Patti on Mass Spec and Multi-Omics In this episode of the ChatGJP series, Panome Bio CSO Gary Patti shares candid insights into his research at Washington University in St. Louis, his work with Panome Bio, and the evolving landscape of mass...
by Jason Heaviland | Nov 24, 2025 | Uncategorized
Biomarker-Driven mRNA Trials: How Discovery Metabolomics Finds the Responders Before Treatment Your Phase 2 mRNA therapeutic trial enrolled sixty patients. Twenty showed remarkable responses. Thirty had modest benefits. Ten showed no response at all. Now you’re...
by Rob Marriott | Aug 22, 2025 | Uncategorized
Blood sampling doesn’t have to be complicated. For decades, Dried Blood Spots (DBS) have offered a simple, scalable alternative to traditional blood plasma collection. However, the use of Dried Blood Spots in advanced untargeted metabolomics has been limited by...
